A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Locally Advanced or Metastatic Breast Cancer
Interventions: DRUG: Phesgo|DRUG: Giredestrant|DRUG: Docetaxel|DRUG: Paclitaxel|DRUG: LHRH Agonist|DRUG: Optional Endocrine Therapy of Investigator's Choice
Sponsor: Hoffmann-La Roche